Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus D Flather

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Circulation|April 20, 2011
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue, Deepak L Bhatt, Stephen D Wiviott, et al.
International Journal of Cardiology|September 24, 2002
Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and designMarcelo C Shibata, Marcus D Flather, Michael Böhm, et al.
JAMA|June 10, 2004
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registryKim A Eagle, Michael J Lim, Omar H Dabbous, et al.
Lancet (London, England)|September 7, 2014
Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysisDipak Kotecha, Jane Holmes, Henry Krum, et al.
Journal of the American College of Cardiology|May 4, 2017
Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart FailureDipak Kotecha, Marcus D Flather, Douglas G Altman, et al.
European Heart Journal|January 12, 2005
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)Marcus D Flather, Marcelo C Shibata, Andrew J S Coats, et al.
Lancet (London, England)|September 2, 2021
Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysisAndreas Karwath, Karina V Bunting, Simrat K Gill, et al.
BMJ (Clinical Research Ed.)|April 22, 2016
Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysisDipak Kotecha, Luis Manzano, Henry Krum, et al.
Journal of the American College of Cardiology|December 7, 2019
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart FailureDipak Kotecha, Simrat K Gill, Marcus D Flather, et al.
European Heart Journal|March 28, 2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics studyDeepak L Bhatt, Guillaume Paré, John W Eikelboom, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Circulation|April 20, 2011
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue, Deepak L Bhatt, Stephen D Wiviott, et al.
International Journal of Cardiology|September 24, 2002
Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and designMarcelo C Shibata, Marcus D Flather, Michael Böhm, et al.
JAMA|June 10, 2004
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registryKim A Eagle, Michael J Lim, Omar H Dabbous, et al.
Lancet (London, England)|September 7, 2014
Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysisDipak Kotecha, Jane Holmes, Henry Krum, et al.
Journal of the American College of Cardiology|May 4, 2017
Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart FailureDipak Kotecha, Marcus D Flather, Douglas G Altman, et al.
European Heart Journal|January 12, 2005
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)Marcus D Flather, Marcelo C Shibata, Andrew J S Coats, et al.
Lancet (London, England)|September 2, 2021
Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysisAndreas Karwath, Karina V Bunting, Simrat K Gill, et al.
BMJ (Clinical Research Ed.)|April 22, 2016
Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysisDipak Kotecha, Luis Manzano, Henry Krum, et al.
Journal of the American College of Cardiology|December 7, 2019
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart FailureDipak Kotecha, Simrat K Gill, Marcus D Flather, et al.
European Heart Journal|March 28, 2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics studyDeepak L Bhatt, Guillaume Paré, John W Eikelboom, et al.
Pageof 8